

WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



ON VINED THE NATION COOREDATION TREATY (DCT)

	43) International Publication Date: 5 June 1997 (05.06.97
21) International Application Number: PCT/US96/18984 22) International Filing Date: 27 November 1996 (27.11.96)	Woods & Goodyear, 1800 One M & T Plaza, Buffalo, N'
30) Priority Data: 08/565,943 1 December 1995 (01.12.95) US	(81) Designated States: AU, CA, JP, KR, MX, NZ, US, Eurasia patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), Europea patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT LU, MC, NL, PT, SE).
71) Applicants (for all designated States except US): UNIVER- SITY OF IOWA RESEARCH FOUNDATION [US/US]; 100 Oakdale Campus #214 TIC, lowa City, IA 52242- 5000 (US). THE REGENTS OF THE UNIVERSITY OF CALIFORNIA [US/US]; 22nd floor, 300 Lakeside Drive, Oakland, CA 94612-3550 (US). AMERICAN CYANAMID COMPANY [US/US]; Five Giralda Farms, Madison, NJ 07940 (US).	Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of
72) Inventors; and 75) Inventors/Applicants (for US only): APICELLA, Michael, A. [-/US]; 2646 Johnsons Crossing, N.E., Solon, IA 52333 (US). SUNSHINE, Melvin, G. [-/US]; 340 Raven Street, Iowa City, IA 52245 (US). LEE, Na-Gyong [-/-]; Apartment 27-1309, Nam-gu Hakik-2-dong, Sindong-a, Incheon (KR). ARUMUGHAM, Rasappa [-/US]; 15 Elatia Circle, Pittsford, NY 14534 (US). GIBSON, Bradford, W. [-/US]; 1324 Peralta Avenue, Berkeley, CA 94702 (US).	

A method is provided for identifying, isolating, and producing htrB mutants of gram-negative bacterial pathogens. The method comprises mutating the htrB gene of a gram-negative bacterial pathogen so that there is a lack of a functional htrB protein, resulting in a mutant that lacks one or more secondary acyl chains contained in the wild type gram-negative bacterial pathogen, and displays substantially reduced toxicity as compared to the wild type strain. Also, the present invention provides methods for using a vaccine formulation containing the hirB mutant, the endotoxin isolated therefrom, or the endotoxin isolated therefrom which is then conjugated to a carrier protein, to immunize an individual against infections caused by gram-negative bacterial pathogens by administering a prophylactically effective amount of the vaccine formulation.

